RT Journal Article SR Electronic T1 Characterising Streptococcus pneumoniae Transmission Patterns in Malawi Through Genomic and Statistical Modelling JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.11.22.24317796 DO 10.1101/2024.11.22.24317796 A1 Cave, Rory A1 Chirombo, James A1 Obolski, Uri A1 Belman, Sophie A1 Kalizang’oma, Akuzike A1 Mwalukomo, Thandie S. A1 Kamng’ona, Arox A1 Brown, Comfort A1 Msefula, Jacquline A1 Bonomali, Farouck A1 Nyirenda, Roseline A1 Swarthout, Todd D. A1 Kwambana-Adams, Brenda A1 French, Neil A1 Heyderman, Robert S. YR 2024 UL http://medrxiv.org/content/early/2024/11/23/2024.11.22.24317796.abstract AB Controlling the carriage and transmission of Streptococcus pneumoniae in children from high- disease burden countries is crucial for disease prevention. To assess the rate of spread, and the factors associated with the high frequency of transmission despite pneumococcal conjugate vaccine (PCV) introduction, we measured evolution divergence time using the whole genome sequences of S. pneumoniae collected from 1,617 child participants from Blantyre, Malawi between 2015 and 2019. These children included both PCV13 vaccinated children aged 2 to 7 years and PCV13 unvaccinated children aged 5 to 10 years who were age ineligible when PCV was introduced. Using a generalized additive mixed model (GAMM) and relative risk (RR) frameworks, while accounting for household geospatial distances, we found that the spread of lineages became widespread across the population of Blantyre over approximately four years, with transmission being more likely between neighbouring households. Logistic regression and random forest models predicted a higher incidence of events among preschool children in densely populated, higher socioeconomic areas. Additionally, recent transmission was linked to recently expanding, non-vaccine serotype lineages that are penicillin non-susceptible. Our findings suggest that enhancing vaccine-mediated immunity among preschool-aged children in high density settings could reduce transmission of disease-causing and antimicrobial-resistant pneumococcal lineages, therefore strengthening herd protection for vulnerable individuals (e.g. very young children and people living with HIV).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funding was awarded to RSH including OPP1117653 Bill & Melinda Gates Foundation https://www.gatesfoundation.org/; MRC Grant Number: MR/N023129/1 Medical Research Council https://www.ukri.org/councils/mrc/; 206545/Z/17/Z The Malawi Liverpool Wellcome Programme is supported by a Strategic Award from the Wellcome Trust https://www.mlw.mw/.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PCVPA study protocol received approval from the College of Medicine Research and Ethics Committee, University of Malawi (P.02/15/1677), and the Liverpool School of Tropical Medicine Research Ethics Committee (14.056). Written informed consent was obtained from adult participants and the parents or guardians of child participants. Children aged 8 to 10 years also provided informed assent. Consent included permission for publicationI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes